Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short term Debt (2018 - 2025)

Historic Short term Debt for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $4475.0.

  • China SXT Pharmaceuticals' Short term Debt fell 9993.99% to $4475.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4475.0, marking a year-over-year decrease of 9993.99%. This contributed to the annual value of $8781.0 for FY2025, which is 9821.91% down from last year.
  • China SXT Pharmaceuticals' Short term Debt amounted to $4475.0 in Q3 2025, which was down 9993.99% from $8781.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Short term Debt high stood at $12.1 million for Q1 2021, and its period low was $4475.0 during Q3 2025.
  • In the last 5 years, China SXT Pharmaceuticals' Short term Debt had a median value of $849580.5 in 2022 and averaged $2.6 million.
  • In the last 5 years, China SXT Pharmaceuticals' Short term Debt surged by 452781.21% in 2021 and then crashed by 9993.99% in 2025.
  • Quarter analysis of 5 years shows China SXT Pharmaceuticals' Short term Debt stood at $2.1 million in 2021, then tumbled by 43.04% to $1.2 million in 2022, then surged by 106.96% to $2.5 million in 2023, then surged by 198.34% to $7.4 million in 2024, then plummeted by 99.94% to $4475.0 in 2025.
  • Its last three reported values are $4475.0 in Q3 2025, $8781.0 for Q1 2025, and $7.4 million during Q3 2024.